170 related articles for article (PubMed ID: 18771083)
1. VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells.
Jia SF; Guan H; Duan X; Kleinerman ES
J Exp Ther Oncol; 2008; 7(2):89-97. PubMed ID: 18771083
[TBL] [Abstract][Full Text] [Related]
2. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression.
Huang G; Nishimoto K; Zhou Z; Hughes D; Kleinerman ES
Cancer Res; 2012 Feb; 72(4):908-16. PubMed ID: 22186140
[TBL] [Abstract][Full Text] [Related]
3. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.
Lafleur EA; Koshkina NV; Stewart J; Jia SF; Worth LL; Duan X; Kleinerman ES
Clin Cancer Res; 2004 Dec; 10(23):8114-9. PubMed ID: 15585647
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.
Rao-Bindal K; Koshkina NV; Stewart J; Kleinerman ES
Curr Cancer Drug Targets; 2013 May; 13(4):411-22. PubMed ID: 23410027
[TBL] [Abstract][Full Text] [Related]
5. Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylation.
Huang G; Koshkina NV; Kleinerman ES
Oncol Res; 2009; 18(1):31-9. PubMed ID: 19911702
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features.
Gutiérrez LM; Valenzuela Alvarez M; Yang Y; Spinelli F; Cantero MJ; Alaniz L; García MG; Kleinerman ES; Correa A; Bolontrade MF
Apoptosis; 2021 Aug; 26(7-8):447-459. PubMed ID: 34024019
[TBL] [Abstract][Full Text] [Related]
7. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
Koshkina N; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242
[TBL] [Abstract][Full Text] [Related]
8. Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells.
Duan X; Jia SF; Zhou Z; Langley RR; Bolontrade MF; Kleinerman ES
Clin Exp Metastasis; 2004; 21(8):747-53. PubMed ID: 16035619
[TBL] [Abstract][Full Text] [Related]
9. miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating
Yang Y; Huang G; Zhou Z; Fewell JG; Kleinerman ES
Mol Cancer Ther; 2018 Jan; 17(1):130-139. PubMed ID: 29079708
[TBL] [Abstract][Full Text] [Related]
10. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
Gordon N; Kleinerman ES
J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):189-96. PubMed ID: 20528149
[TBL] [Abstract][Full Text] [Related]
11. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.
Koshkina NV; Rao-Bindal K; Kleinerman ES
Cancer; 2011 Aug; 117(15):3457-67. PubMed ID: 21287529
[TBL] [Abstract][Full Text] [Related]
12. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.
Huang G; Nishimoto K; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2014; 804():203-17. PubMed ID: 24924176
[TBL] [Abstract][Full Text] [Related]
13. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
Wang SW; Liu SC; Sun HL; Huang TY; Chan CH; Yang CY; Yeh HI; Huang YL; Chou WY; Lin YM; Tang CH
Carcinogenesis; 2015 Jan; 36(1):104-14. PubMed ID: 25330803
[TBL] [Abstract][Full Text] [Related]
14. CCL3 promotes angiogenesis by dysregulation of miR-374b/ VEGF-A axis in human osteosarcoma cells.
Liao YY; Tsai HC; Chou PY; Wang SW; Chen HT; Lin YM; Chiang IP; Chang TM; Hsu SK; Chou MC; Tang CH; Fong YC
Oncotarget; 2016 Jan; 7(4):4310-25. PubMed ID: 26713602
[TBL] [Abstract][Full Text] [Related]
15. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
Gordon N; Kleinerman ES
Cancer Treat Res; 2009; 152():497-508. PubMed ID: 20213411
[TBL] [Abstract][Full Text] [Related]
16. Fas expression inversely correlates with metastatic potential in osteosarcoma cells.
Worth LL; Lafleur EA; Jia SF; Kleinerman ES
Oncol Rep; 2002; 9(4):823-7. PubMed ID: 12066216
[TBL] [Abstract][Full Text] [Related]
17. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases.
Koshkina NV; Kleinerman ES
Int J Cancer; 2005 Sep; 116(3):458-63. PubMed ID: 15800950
[TBL] [Abstract][Full Text] [Related]
18. The Role of FAS Receptor Methylation in Osteosarcoma Metastasis.
Sun JM; Chow WY; Xu G; Hicks MJ; Nakka M; Shen J; Ng PKS; Taylor AM; Yu A; Farrar JE; Barkauskas DA; Gorlick R; Guidry Auvil JM; Gerhard D; Meltzer P; Guerra R; Man TK; Lau CC; On Behalf Of The Target Osteosarcoma Consortium
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569529
[TBL] [Abstract][Full Text] [Related]
19. Altered morphology, nuclear stability and adhesion of highly metastatic derivatives of osteoblast-like SAOS-2 osteosarcoma cells.
Muff R; Nigg N; Gruber P; Walters D; Born W; Fuchs B
Anticancer Res; 2007; 27(6B):3973-9. PubMed ID: 18225558
[TBL] [Abstract][Full Text] [Related]
20. Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy.
Tanaka T; Yui Y; Naka N; Wakamatsu T; Yoshioka K; Araki N; Yoshikawa H; Itoh K
Clin Exp Metastasis; 2013 Apr; 30(4):369-79. PubMed ID: 23076771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
